AbbVie, Genmab tout Epkinly combos in earlier lines of non-Hodgkin lymphoma

SAN DIEGO — AbbVie and Genmab are building the case for their bispecific Epkinly in earlier lines of treatment, presenting longer-term combination data in two types …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca criticizes CMS guidance in appeal over price negotiations

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 17, 2024

AI-READI consortium launches groundbreaking diabetes data study

Researchers today (Nov. 8, 2024) are releasing the flagship dataset from an ambitious study of biomarkers and environmental factors that might influence the development of

November 8, 2024

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th – Psychedelic Alpha

Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a

October 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.